Mylan NV (MYL)

40.36
1.40 3.30
NASDAQ : Health Care
Prev Close 41.72
Open 41.50
Day Low/High 40.13 / 41.89
52 Wk Low/High 37.59 / 67.34
Volume 10.19M
Avg Volume 5.87M
Exchange NASDAQ
Shares Outstanding 535.50M
Market Cap 22.34B
EPS 1.80
P/E Ratio 45.34
Div & Yield N.A. (N.A)

Latest News

Crude Rally Boosts Energy Stocks, S&P 500 Inches Higher

Crude Rally Boosts Energy Stocks, S&P 500 Inches Higher

The S&P 500 inches higher in mixed trading Wednesday as a rally in crude helps the energy sector.

Mylan Hires Former SEC Commissioner for Chief Legal Officer Position

Mylan Hires Former SEC Commissioner for Chief Legal Officer Position

The company could be gearing up for multiple challenges on the D.C. front, analysts say.

Impax Gains 38% On CEO Appointment, Talk of Sale

Impax Gains 38% On CEO Appointment, Talk of Sale

The company hired Paul Bisaro, former chairman at Allergan, to become CEO as Morgan Stanley helps explore alternatives, including a sale.

Can This Pharma Stock Withstand the 'Trump Effect'?

Can This Pharma Stock Withstand the 'Trump Effect'?

With a 100-plus-year history, generous dividend, and diversified portfolio, could this Big Pharma player be resistant to Trump's drug price twitterstorm?

Mylan Hit After Abbott Dumps Shares

Mylan Hit After Abbott Dumps Shares

The company decreased its 13% stake in Mylan Friday.

Immunomedics, Mylan Lead Biotech Movers

Immunomedics, Mylan Lead Biotech Movers

Investors weren't completely distracted by the Affordable Care Act debate.

Mylan's Government Connections Go Deeper Than Initially Reported

Mylan's Government Connections Go Deeper Than Initially Reported

Mylan CEO Heather Bresch's father sponsored a bill that made it easier for generic drugs to be substituted back in 1986. This helped Mylan become the largest generic manufacturer.

Mylan Receives Tentative Approval For

Mylan Receives Tentative Approval For "TLE400" Under PEPFAR

- TLE400 is a fixed-combination containing Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg -

Mylan Settles With Genentech Over Patents for Breast Cancer Drug

Mylan Settles With Genentech Over Patents for Breast Cancer Drug

The settlement provides Mylan with global licenses for its trastuzumab product.

Why Battered Biotech Teva Is a Smart Contrarian Buy Right Now

Why Battered Biotech Teva Is a Smart Contrarian Buy Right Now

A firestorm in Washington has created a fire sale for shares of this undervalued stock.

Politicians Question EpiPen Competitor's High Pricetag

Politicians Question EpiPen Competitor's High Pricetag

Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Bull Markets and Drug Rallies: Jim Cramer's Best Blog

Jim Cramer ponders the bull market and whether the drug rally is 'Trumped up.'

Mylan's Governance May Be the Root of Its Problems

Mylan's Governance May Be the Root of Its Problems

The scandals plaguing the pharmaceutical company can be traced to lack of change at the board level.

Is This The Best Biotech Play for 2017?

Is This The Best Biotech Play for 2017?

Is this small-cap biotech play the best way to profit from the growing worldwide demand for vaccines?

Twenty More States Accuse Mylan, Teva and Others of Price Collusion

Twenty More States Accuse Mylan, Teva and Others of Price Collusion

Forty states have now sued the companies.

Dow Adds 300 Points as Stocks Enjoy Best Day of 2017 on Optimism Over U.S. Economy

Dow Adds 300 Points as Stocks Enjoy Best Day of 2017 on Optimism Over U.S. Economy

Stocks enjoy their best gains of the year as investors rejoice over the Federal Reserve's apparent faith in the U.S. economy.

Stocks Hold Big Gains, Dow Hits 21,000 on Optimism Over U.S. Economy

Stocks Hold Big Gains, Dow Hits 21,000 on Optimism Over U.S. Economy

Stocks hold big gains through Wednesday morning, trading at all-time highs, as investors rejoice over the Federal Reserve's apparent faith in the U.S. economy.

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Impax Laboratories, Clearside Biomedical and Mylan were among the biotech stock movers in premarket trading Wednesday.

Stock Futures Higher as Chances Rise of a Rate Hike in March

Stock Futures Higher as Chances Rise of a Rate Hike in March

Stock futures suggest Wall Street would get back to its record-breaking ways on Wednesday as chances rose of a return to normal U.S. monetary policy sooner rather than later.

Mylan Stock Spikes on Earnings Beat

Mylan Stock Spikes on Earnings Beat

Mylan topped bottom line estimates by 15 cents.

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.